Hemogenomics Private Limited - Due diligence report

A 360° intelligence report on Hemogenomics: trust score, financial health, credit view, compliance, directors, growth and distress signals -…

2002-01-22 Bangalore., Karnataka Active Unlisted Active Compliant
Share
View plans Plan
HP Hemogenomics Private Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Hemogenomics — 360° Intelligence Report

Generated from MCA filings & public records
87/100
Trust Score
Low Risk

Hemogenomics is assessed as Low Risk with a Trust Score of 87/100. Hemogenomics is an active private limited indian non-government company incorporated in 2002, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 07 Jul 2026 from the latest processed filings. Hemogenomics Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 4 open (68.54 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.2 48.0 cr
The Hongkong And Shanghai Banking Corporation Limited1 48.0 cr
Others1 48.0 cr
Compliance Score: 80/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 3 court forum(s).
  • 6 active GST registration(s).
Legal cases on record (3)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
ANURAG BAGARIA 01234567 Director 01/04/2018 6 yrs Approved
SUMIT BAGARIA 01234567 Director 01/04/2018 6 yrs Approved
Francisco Jose Dopazo Gonzalez 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 2 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
1 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
Indian Foundation For Safe Blood Associate Company 74.00%

Key managerial personnel: SUMIT BAGARIA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 24+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 24% in a year.
4 open charge(s) registered - assets are encumbered.
3 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 68.54 cr already registered.
  • Compliance record supports lending.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
Francisco Jose Dopazo Gonzalez
28 Jun 2025
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 27.50 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Feb 2025
Charge created
Others - 1.04 cr
10 Jan 2025
Director appointed
Francisco Jose Dopazo Gonzalez (Director)
Director ceased
WILLIAM J RUTTER
31 Mar 2016
Share transfer (FY 2016)
50000.00000000 shares to SUMIT BAGARIA
Share transfer (FY 2016)
195000.00000000 shares to SUMIT BAGARIA
21 Mar 2016
Securities allotted
291224 Equity Shares - 29.12 Lakh raised
02 Mar 2016
Charge created
Citi Bank N.A. - 5.00 cr
07 Apr 2015
Director ceased
NARAYANAN VAGHUL
11 Jan 2012
Charge created
Citi Bank N.A. - 35.00 cr
18 Jan 2011
Director appointed
SUMIT BAGARIA (Managing Director)
11 Nov 2010
Director ceased
ASHOK SEKHAR GANGULY
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
6 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ams Polymers Limited L34300DL1985PLC020510 Delhi, Delhi, India
Vishal Karnataka Trade Links Private Limited U27310KA1993PTC014864 Bangalore., Karnataka, India
Sigma Esolution Private Limited U72200JH2008PTC013124 Ranchi, Jharkhand, India
Vaishalipharma L52310MH2008PLC181632 Mumbai, Maharashtra, India
Silicon Rental Solutions L74999MH2016PLC272442 Mumbai, Maharashtra, India
Gtv L31102MP1990PLC006122 Mandideep, Madhya Pradesh, India
Purple United Sales Limited L51909DL2014PLC271636 New Delhi, Delhi, India
Shree Metalloys L67120GJ1994PLC023471 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Hemogenomics before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Hemogenomics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Hemogenomics - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Hemogenomics pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Hemogenomics - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Hemogenomics an active company?

Hemogenomics has MCA status “Active” with a compliance score of 80/100 (Low Risk).

Is Hemogenomics financially healthy?

Hemogenomics has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Hemogenomics?

Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Hemogenomics?

Promoters hold a majority stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Hemogenomics have loans or charges against its assets?

4 open charge(s) are registered against its assets.

Is Hemogenomics up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 80/100 (Low Risk).

Is it risky to lend to Hemogenomics?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.